oxidopamine has been researched along with Tardive Dyskinesia in 1 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Tardive Dyskinesia: Drug-related movement disorder characterized by uncontrollable movements in certain muscles. It is associated with a long-term exposure to certain neuroleptic medications (e.g., METOCLOPRAMIDE).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lindenbach, D | 1 |
| Conti, MM | 1 |
| Ostock, CY | 1 |
| George, JA | 1 |
| Goldenberg, AA | 1 |
| Melikhov-Sosin, M | 1 |
| Nuss, EE | 1 |
| Bishop, C | 1 |
1 other study available for oxidopamine and Tardive Dyskinesia
| Article | Year |
|---|---|
The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, | 2016 |